Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ISIS-APOCIIIRx: Phase II data

A double-blind Phase II trial in 11 Type II diabetics with high triglyceride levels (200-500 mg/dL) showed that once-weekly 300 mg subcutaneous ISIS-APOCIIIRx met the primary endpoint

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE